東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Pharmacogenetics of antidepressant r...

Peters, Eric James.

Linked to FindBook

Google Book

Amazon

博客來

Pharmacogenetics of antidepressant response.

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Pharmacogenetics of antidepressant response./
Author:	Peters, Eric James.
Description:	263 p.
Notes:	Adviser: Steven P. Hamilton.
Contained By:	Dissertation Abstracts International68-02B.
Subject:	Biology, Genetics. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3251935

Pharmacogenetics of antidepressant response.
Peters, Eric James.

Pharmacogenetics of antidepressant response. - 263 p.

Adviser: Steven P. Hamilton.

Thesis (Ph.D.)--University of California, San Francisco, 2007.

Major depressive disorder is one of the most common and debilitating psychiatric disorders. While psychopharmacological treatments exist, they are not universally effective and can produce significant side effects in some patients. The most common psychopharmacological agents used to treat major depression are the selective serotonin reuptake inhibitors, or SSRIs. Often, these drugs take several weeks to relieve depressive symptoms. If the initial therapy fails, other antidepressants are often prescribed. This "trial and error" process creates a delay in remission which can be frustrate the patient and lead to further decreased well-being. Individualized therapy would have great clinical utility by identifying patients that are likely to respond positively to SSRI therapy. The goal of this thesis is to investigate the use of genetic markers for guiding treatment with SSRIs.Subjects--Topical Terms:

1017730
Biology, Genetics.

Pharmacogenetics of antidepressant response.
LDR:03299nam 2200277 a 45 001 938904
005 20110512
008 110512s2007 eng d
035 $a (UMI)AAI3251935
035 $a AAI3251935
040 $a UMI $c UMI
100 1 $a Peters, Eric James. $3 1262875
245 1 0 $a Pharmacogenetics of antidepressant response.
300 $a 263 p.
500 $a Adviser: Steven P. Hamilton.
500 $a Source: Dissertation Abstracts International, Volume: 68-02, Section: B, page: 0746.
502 $a Thesis (Ph.D.)--University of California, San Francisco, 2007.
520 $a Major depressive disorder is one of the most common and debilitating psychiatric disorders. While psychopharmacological treatments exist, they are not universally effective and can produce significant side effects in some patients. The most common psychopharmacological agents used to treat major depression are the selective serotonin reuptake inhibitors, or SSRIs. Often, these drugs take several weeks to relieve depressive symptoms. If the initial therapy fails, other antidepressants are often prescribed. This "trial and error" process creates a delay in remission which can be frustrate the patient and lead to further decreased well-being. Individualized therapy would have great clinical utility by identifying patients that are likely to respond positively to SSRI therapy. The goal of this thesis is to investigate the use of genetic markers for guiding treatment with SSRIs.
520 $a We utilized several complementary pharmacogenetic approaches and two depressed populations treated with SSRIs. The first was a small (N=96) population given fluoxetine, and the second was a large (N=1,953) population taking citalopram. We used the fluoxetine population and a linkage disequilibrium mapping approach to investigate variants in seven pharmacodynamic candidate genes for association to response and specificity of response. Several variants in HTR2A and TPH1 were associated with fluoxetine outcome. We then resequenced the coding region and 5' conserved non-coding regions of these genes in the fluoxetine population in order to uncover novel variation and additional tagging SNPs. These tagging SNPs were genotyped in our citalopram population, and none of the SNPs were associated with clinical outcome. We then genotyped known, functional polymorphisms in relevant pharmacokinetic genes for association to citalopram response and tolerance. Using a two-stage study design, none of the variants were significantly associated with outcome following citalopram treatment. We also utilized a whole genome association study using over 590,000 SNPs from across the genome. Using a two-stage study design, none of the most highly associated markers in the discovery sample were also associated in the validation sample. Similar non-significant results were obtained using multi-SNP decision trees. However, further genotyping is necessary in the validation sample, as the most highly associated SNPs may not be the most consistently associated.
590 $a School code: 0034.
650 4 $a Biology, Genetics. $3 1017730
650 4 $a Health Sciences, Pharmacology. $3 1017717
690 $a 0369
690 $a 0419
710 2 0 $a University of California, San Francisco. $3 1025118
773 0 $t Dissertation Abstracts International $g 68-02B.
790 $a 0034
790 1 0 $a Hamilton, Steven P., $e advisor
791 $a Ph.D.
792 $a 2007
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3251935